Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

GSK-3beta inhibitor and application as novel target spot for diabetic nephropathy intervention

A technology for diabetic nephropathy and β-inhibitor, applied in the field of medical preparations, can solve problems such as inability to have both renal protection effects, limited renal protection effects, and reduction of proteinuria in patients, so as to enhance podocyte protection effect and improve renal protection. effect, podocyte damage reduction effect

Inactive Publication Date: 2019-03-12
THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In summary, the problems in the prior art are: In some treatment techniques, high-glucose-induced podocyte damage is more serious; in the clinical treatment of DN patients, while reducing proteinuria, it cannot protect the kidneys at the same time
The most similar existing treatment technology uses reduced glutathione added to normal saline for intravenous infusion to exert its own antioxidant effect, but the protective effect on the kidney is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • GSK-3beta inhibitor and application as novel target spot for diabetic nephropathy intervention

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] In order to make the object, technical solution and advantages of the present invention more clear, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0011] The application principle of the present invention will be described in detail below in conjunction with the accompanying drawings.

[0012] GSK-3β inhibitor regulates the accumulation of Nrf2 in the nucleus and binds to antioxidant response elements, up-regulates the expression level of antioxidant proteins, enhances the protective effect of podocytes, and exerts a better renal protective effect through the cascade amplification effect, and lithium The agent can increase the level of glutathione and the activity of SOD in the tissue, and play an antioxidant role.

[0013] The GSK-3β inhibitor LiCl provided in the e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medical preparations containing effective components, and discloses application of a GSK-3beta inhibitor as a novel target spot for diabetic nephropathyintervention. According to a method for using the GSK-3beta inhibitor as the novel target spot for diabetic nephropathy intervention, an siRNA technology and an inhibitor of the siRNA technology areused, so that the fact that after expression or activity of GSK-3beta is inhibited, podocyte injury caused by high glucose is relieved to some extent is found, and means that the GSK-3beta participates in a podocyte injury process caused by the high glucose, and plays an important part; studies of animal experiments further prove a conclusion drawn on a cellular level, and the fact that the GSK-3beta inhibitor can relieve podocyte injury, caused by the high glucose, and proteinuria is proven again, so that a novel idea is provided for finding a novel treatment measure of diabetic nephropathy.

Description

technical field [0001] The invention belongs to the technical field of medical preparations containing active ingredients, and in particular relates to a GSK-3β inhibitor and its application in new targets for diabetic nephropathy intervention. Background technique [0002] At present, the existing technologies commonly used in the industry are as follows: Diabetic nephropathy (DN) is the most common microvascular complication in patients with Diabetes Mellitus (DM) and one of the important causes of end-stage renal disease, with proteinuria as the main clinical manifestation. Current studies suggest that podocyte injury is an important mechanism of proteinuria, but the mechanism of high glucose-induced podocyte injury still needs further study. DN is the most serious and harmful chronic complication caused by DM. Glomerulosclerosis caused by microangiopathy caused by diabetes is the characteristic of this disease. It is also the main cause of death in DM patients. Infect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/00A61P3/10A61P13/12
CPCA61K33/00A61P3/10A61P13/12
Inventor 刘东伟刘章锁乔颖进郭佳潘少康刘风勋段家宇逯明蕾
Owner THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com